ResMed Announces Participation in the Morgan Stanley 22nd Annual Global Healthcare Conference
28. August 2024 16:05 ET
|
ResMed Inc.
SAN DIEGO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, Chairman and Chief Executive Officer, and Dr. Carlos Nunez, Chief Medical Officer, will...
ResMed Expands its Board of Directors and Appoints Healthcare Executive and Seasoned Finance Leader Christopher DelOrefice to its Board
15. August 2024 16:05 ET
|
ResMed Inc.
DelOrefice is the Chief Financial Officer at BD, one of the largest global MedTech companies in the worldBoard appointment brings over 30 years of strategic and operational finance expertise SAN...
ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2024
01. August 2024 16:05 ET
|
ResMed Inc.
Year-over-year revenue grows 9%, operating profit up 38%, non-GAAP operating profit up 30%Operating cash flow of $440 millionQuarterly dividend increases 10% to $0.53 per shareCompany to host an...
ResMed to Report Fourth Quarter Fiscal 2024 Earnings on August 1, 2024
03. Juli 2024 16:05 ET
|
ResMed Inc.
SAN DIEGO, July 03, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2024 on...
PAP Therapy Reduces Hospitalizations by 31% and ER Visits by 23% for People with Obstructive Sleep Apnea and Comorbid Insomnia
10. Juni 2024 09:05 ET
|
ResMed Inc.
ResMed-supported research presented at SLEEP2024 demonstrates the effectiveness and value of positive airway pressure (PAP) treatment for OSA.
Developed in Collaboration with Leading Scientists, New ResMed-Supported Research at ATS 2024 Provides Evidence of the Effectiveness and Critical Role of Positive Airway Pressure Therapy
23. Mai 2024 09:05 ET
|
ResMed Inc.
New ResMed-Supported Research at ATS 2024 Provides Evidence of the Effectiveness and Critical Role of Positive Airway Pressure Therapy
ATS 2024: New ResMed-Supported Research Shows Increasing Prevalence of Obstructive Sleep Apnea and Critical Role of PAP Therapy
16. Mai 2024 16:35 ET
|
ResMed Inc.
ATS 2024: New ResMed-Supported Research Shows
Increasing Prevalence of Obstructive Sleep Apnea and Critical Role of PAP Therapy
ResMed Announces Participation in the RBCCM Global Healthcare Conference
07. Mai 2024 16:05 ET
|
ResMed Inc.
SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Dr. Carlos Nunez, Chief Medical Officer, and Amy Wakeham, Chief Investor Relations Officer, will participate...
ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2024
25. April 2024 16:05 ET
|
ResMed Inc.
Year-over-year revenue grows 7%, operating profit up 25%, non-GAAP operating profit up 23%Operating cash flows of $402 million Note: A webcast of ResMed’s conference call will be available at...
ResMed to Report Third Quarter Fiscal 2024 Earnings on April 25, 2024
04. April 2024 16:05 ET
|
ResMed Inc.
SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2024 on...